Abstract 1501TiP
Background
Non-small cell lung cancer (NSCLC) encompasses over two-thirds of lung cancer diagnoses, most presenting as advanced disease. c-Met (MET protein) is overexpressed in NSCLC. In this study, we investigate telisotuzumab vedotin (Teliso-V), a first-in-class antibody-drug conjugate composed of a c-Met–targeting antibody (telisotuzumab) and a microtubule polymerization inhibitor (cytotoxin monomethyl auristatin E). Interim efficacy analysis of the phase 2 LUMINOSITY study (NCT03539536) of Teliso-V monotherapy showed an objective response rate (ORR) of 37% (95% CI: 24–51) in previously treated patients (pts) with c-Met overexpressing epidermal growth factor receptor (EGFR) wildtype (WT) nonsquamous NSCLC and 52% (95% CI: 31–73) in the high c-Met overexpressing group.
Trial design
This randomized, open-label, global phase 3 study (NCT04928846) evaluates the efficacy, safety, pharmacokinetics, and pharmacodynamics of Teliso-V monotherapy compared with docetaxel in pts with locally advanced/metastatic c-Met overexpressing EGFR WT nonsquamous NSCLC who have progressed on prior therapy. Enrollment began in May 2022. To be eligible across global sites, pts must be ≥18 years old with c-Met overexpressing (ie, ≥25% tumor cells at 3+ intensity by IHC assay [anti-MET clone SP44; Roche Tissue Diagnostics]) locally advanced/metastatic EGFR WT NSCLC, with ECOG score ≤1. Pts must have progressed on at least one prior line of therapy, which can include no more than one line of prior chemotherapy, and must be naïve to c-Met–targeted antibodies and docetaxel. Target enrollment is 698 pts. Pts will be randomized 1:1 to Teliso-V (1.9 mg/kg every 2 weeks) and docetaxel (control, 75 mg/m2 every 3 weeks). Treatment continues until disease progression or discontinuation criteria are met. Co-primary endpoints are progression-free survival by independent central review and overall survival. Secondary endpoints include ORR, duration of response, and patient-reported outcomes. Safety, adverse events (AEs), drug discontinuation or dosing modification due to AEs, and tolerability will be assessed.
Clinical trial identification
NCT04928846.
Editorial acknowledgement
Medical writing support was provided by Ana Lopez, PhD, of Fishawack Facilitate Ltd, and funded by AbbVie.
Legal entity responsible for the study
AbbVie.
Funding
AbbVie.
Disclosure
A. Lugini: Financial Interests, Personal and Institutional, Advisory Role: Roche, MSD, Boehringer Ingelheim, AstraZeneca, BMS, Sanofi-Regeneron. J.W. Goldman: Financial Interests, Personal and Institutional, Research Grant: AbbVie, AstraZeneca, Bristol Myers Squibb, Eli Lilly and Company, Genentech, Merck, Pfizer; Financial Interests, Personal and Institutional, Advisory Role: AbbVie, AstraZeneca, Bristol Myers Squibb, Genentech, Pfizer. J. Tanizaki: Financial Interests, Personal and Institutional, Invited Speaker: AstraZeneca, Boehringer Ingelheim , Bristol Myers Squibb, Chugai Pharmaceutical, Daiichi Sankyo, Eli Lilly, Janssen Pharmaceutical, MSD, Nihon Medi-Physics, Nippon Kayaku, Taiho Pharmaceutical, Ono Pharmaceutical, Pfizer; Financial Interests, Personal and Institutional, Advisory Role: Boehringer Ingelheim. H. Akamatsu: Financial Interests, Personal and Institutional, Other, Lecturer: MSD, Eli Lily, Amgen Inc, Chugai Pharmaceutical, Ono Pharmaceutical, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Novartis Pharma, Taiho Pharmaceutical, Pfizer, Nippon Kayaku, Daiichi Sankyo, Janssen Pharma; Financial Interests, Personal and Institutional, Research Grant: MSD, Eli Lilly, Amgen Inc. S. Xia, C. Ratajczak, M. Li, E. Bolotin,J. Seraj: Financial Interests, Personal and Institutional, Full or part-time Employment, May hold stock or options: AbbVie. S. Lu: Financial Interests, Personal and Institutional, Research Grant: AstraZeneca, Hutchison, Bristol Myers Squibb, Heng Rui, Roche; Financial Interests, Personal and Institutional, Invited Speaker: AstraZeneca, Roche, Hansoh; Financial Interests, Personal and Institutional, Advisory Role: AstraZeneca, Boehringer Ingelheim, Hutchison, MediPharma, Simcere, ZaiLab, GenomiCare, Roche.
Resources from the same session
1543P - Clinical study of camrelizumab combined with docetaxel and carboplatin in neoadjuvant treatment of locally advanced oesophageal squamous cell carcinoma
Presenter: Rui Wang
Session: Poster session 21
1544P - Camrelizumab plus albumin-bound paclitaxel and S-1 as first-line treatment of advanced gastric/gastroesophageal junction cancer: A phase II clinical trial
Presenter: Xin fang Hou
Session: Poster session 21
1545P - Phase II trial of endostar in combination with concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of esophagus
Presenter: Yuexiao Qi
Session: Poster session 21
1546P - Safety, efficacy, and biomarkers for ONO-4578 plus nivolumab in unresectable advanced or recurrent gastric or gastroesophageal cancer
Presenter: Hidekazu Hirano
Session: Poster session 21
1547P - SNP discovery based on transcriptome sequencing of whole blood RNA to find predictive biomarkers for nivolumab in gastric cancer
Presenter: Chiaki Inagaki
Session: Poster session 21
1549P - A prospective study of circulating tumor DNA (ctDNA) genomic profiling in gastric or gastroesophageal junction (GEJ) cancer patients with recurrence after adjuvant chemotherapy: Liquid-GEAR trial
Presenter: Hiroyuki Takeda
Session: Poster session 21
1551P - Clinicopathologic characteristics and genomic profiling of HER2-low advanced gastric cancer
Presenter: Choong-kun Lee
Session: Poster session 21
1552P - Clinical multi-omics analysis of gastric cancer (GC) in Europe (EU) and Latin America (LatAm): The LEGACy project
Presenter: Tania Fleitas
Session: Poster session 21
1553P - Blood-borne assessment of stromal activation in esophageal adenocarcinoma to guide tocilizumab therapy: A randomized phase II proof-of-concept study
Presenter: Benthe Doeve
Session: Poster session 21